NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
Multivariate analyses reveal that pathologic complete response is associated with transcriptomic differences and chemotherapy type, rather than self-reported race IRVINE, Calif., and AMSTERDAM, May 1, 2026 — Agendia®, Inc., a leader in precision oncology Read More
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics IRVINE, Calif. & AMSTERDAM--Agendia®, Inc., a leader in precision oncology for breast cancer, Read More
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes IRVINE, Calif., and AMSTERDAM — March Read More
Newsroom
News, Stories & Breast Cancer Blog
Anthracycline Chemotherapy Benefit in HR+/HER2− Early-Stage Breast Cancer Treatment
After a diagnosis of early-stage hormone receptor–positive (HR+) and HER2-negative (HER2–) breast cancer, conversations with your oncology team about treatment options may include whether chemotherapy should be part of your care. One of the Read More
Understanding Risk of Recurrence in Breast Cancer
Hearing the words “You have breast cancer” can change everything in an instant. It’s an overwhelming moment—filled with uncertainty, hope, and countless decisions about surgery, chemotherapy, radiation, and recovery. Yet, even after treatment ends, a single, Read More
For Breast Cancer Patients, Genomic Tests Enable Personalized Treatment Options
Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make personalized care decisions. For the more than 300,000 women diagnosed with breast cancer Read More
Early Breast Cancer: Personalizing Chemotherapy Decisions
Using real-world data from the FLEX registry, MammaPrint, a 70-gene signature for risk of distant recurrence, was found to be predictive of chemotherapy benefit and distant recurrence-free interval prognosis in early-stage breast cancer. Read More
SABCS25: Agendia’s Genomic Testing Guides Breast Cancer Care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer. Agendia, a precision oncology company focused on early-stage breast Read More
Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Bar, MD, PhD , Steven J. Isakoff , MD, PhD , Seth A. Wander , MD, PhD Title: Leveraging real-world evidence to personalize adjuvant therapy Read More
Mapping Your Path: How Genomic Testing Can Personalize Your Breast Cancer Treatment Plan
Genomic testing can help personalize your breast cancer treatment plan by helping map a path ahead. When navigating a breast cancer diagnosis, it can feel like approaching one fork in the road after another. Read More
